The American College of Cardiology and the American Heart Association issued new scientific statements advocating use of quantified coronary plaque analyses in management of patients with coronary artery disease. The statements move plaque analysis based on AI-powered coronary computed tomography angiography to a defined clinical consideration in cardiac management, up from "an emerging technology."

White House steps in on preemption of state AI law 

The Trump administration has made known that it intends to foster rapid adoption of AI, starting with a repeal of an executive order (EO) issued by the Biden administration. Now, the White House has issued an EO that would override state AI law, a move that addresses a task that Congress to date has failed to complete. The Biden administration’s October 2023 EO called on members of all industries to notify the White House when developing a foundation AI model, although this order lacked statutory backing. The Trump administration repealed that EO, and Congress has in the meantime tentatively approached legislation that would preempt state AI law. There is at present little confidence that Congress will be able to push any preemptive legislation through, however.

Researchers discover how glioblastoma tumors dodge chemotherapy

Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers new clues for future therapies. Glioblastoma is one of the deadliest brain cancers, accounting for about half of all brain tumors, with a median survival rate of just 15 months. Despite surgery and chemotherapy, more than 1,250 clinical trials over the past 20 years have struggled to improve survival rates.

Rare diseases drive November’s US drug approvals

The U.S. FDA approved 18 drugs in November 2025, including four new molecular entities. Notably, two of the NMEs targeted rare diseases: UCB SA’s Kygevvi for thymidine kinase 2 deficiency and Arrowhead Pharmaceuticals Inc.’s Redemplo (plozasiran) for familial chylomicronemia syndrome.

Also in the news

Accendra Health, Biotronik Neuro, Curasight, Envue Medical, Huxley Medical, Liviliti Health Products, Linus Health, Medline, Medipost, Neuraworx, Nexus Neurotech, Owens & Minor, Pearl, Profound Medical, Soin Neuroscience, Teikoku Seiyaku, Trace Medical